Evolution of human cytomegalovirus-seronegative donor/-seropositive recipient high-risk combination frequency in allogeneic hematopoietic stem cell transplantations at Institute of Hematology and Blood Transfusion during 1995-2014

Transplant Infectious Disease

Volumn 18, Issue 2, 2016, Pages 297-301

  Nemeckova, Sarka ^a   Sroller, V ^a   Stastna Markova, M ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Graft donor; Human cytomegalovirus; Recipient; Seroprevalence

Indexed keywords

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; MAJOR CLINICAL STUDY; ORGAN DONOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROPREVALENCE; ADVERSE EFFECTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CZECH REPUBLIC; DONOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CZECH REPUBLIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; RETROSPECTIVE STUDIES; TISSUE DONORS; VIRUS ACTIVATION;

EID: 84963674106     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12508     Document Type: Article

References (11)

1. Hebart H, Einsele H. Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 2004; 65: 432-436.
2. Broers AE, van Der HR, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95: 2240-2245.
3. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003; 102: 4255-4260.
4. Ljungman P, Brand R, Hoek J, et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis 2014; 59: 473-481.
5. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314: 1006-1010.
6. Roubalova K, Seeman J. Serological survey of antibodies against CMV, EBV, VZV (Sérologický přehled protilátek proti herpetickým virům CMV, EBV, VZV). Zprávy CEM (SZÚ, Praha) 1998; 7 (Suppl. 1): 29-31.
7. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010; 20: 202-213.
8. Lubeck PR, Doerr HW, Rabenau HF. Epidemiology of human cytomegalovirus (HCMV) in an urban region of Germany: what has changed? Med Microbiol Immunol 2010; 199: 53-60.
9. Enders G, Daiminger A, Lindemann L, et al. Cytomegalovirus (CMV) seroprevalence in pregnant women, bone marrow donors and adolescents in Germany, 1996-2010. Med Microbiol Immunol 2012; 201: 303-309.
10. Hoshiba T, Asamoto A, Yabuki Y. [Decreasing seropositivity of cytomegalovirus of pregnant women in Japan.] Nihon Rinsho 1998; 56: 193-196.
11. de Ory F, Ramirez R, Garcia CL, Leon P, Sagues MJ, Sanz JC. Is there a change in cytomegalovirus seroepidemiology in Spain? Eur J Epidemiol 2004; 19: 85-89.